Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Combined With Neoadjuvant Chemotherapy (TPF) in Resectable Locally Advanced HNSCC
NCT05351762Phase 2Unknown
- Sponsor
- Xijing Hospital
- Start
- Jul 2022
- Primary completion
- May 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Xijing Hospital. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05351762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351762.